Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANAB Stock Forecast 2026-2027
$67.51
Current Price
$1.94B
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ANAB Price Targets
+107.4%
To High Target of $140.00
+11.1%
To Median Target of $75.00
-25.9%
To Low Target of $50.00
ANAB Price Momentum
-1.8%
1 Week Change
+8.2%
1 Month Change
+228.5%
1 Year Change
+39.3%
Year-to-Date Change
-7.9%
From 52W High of $73.30
+294.7%
From 52W Low of $17.11
📊 TOP ANALYST CALLS
Did ANAB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AnaptysBio is one of their latest high-conviction picks.
Latest ANAB Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, ANAB has a bullish consensus with a median price target of $75.00 (ranging from $50.00 to $140.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $67.51, the median forecast implies a 11.1% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by John Lee at Truist Securities, suggesting a 25.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANAB Analyst Ratings
11
Buy
1
Hold
0
Sell
ANAB Price Target Range
Low
$50.00
Average
$75.00
High
$140.00
Current: $67.51
Latest ANAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2026 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $95.00 |
| Mar 30, 2026 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $66.00 |
| Mar 17, 2026 | UBS | Michael Yee | Buy | Maintains | $90.00 |
| Mar 12, 2026 | Wedbush | Martin Fan | Outperform | Maintains | $75.00 |
| Mar 9, 2026 | Truist Securities | John Lee | Hold | Maintains | $50.00 |
| Mar 5, 2026 | Stifel | Alex Thompson | Buy | Maintains | $85.00 |
| Mar 4, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $79.00 |
| Mar 4, 2026 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $66.00 |
| Jan 20, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $78.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $70.00 |
| Dec 17, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $55.00 |
| Dec 11, 2025 | Stifel | Alex Thompson | Buy | Maintains | $56.00 |
| Nov 24, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $51.00 |
| Nov 24, 2025 | Wedbush | Martin Fan | Outperform | Reiterates | $50.00 |
| Nov 11, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $52.00 |
| Nov 11, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $70.00 |
| Nov 10, 2025 | Truist Securities | John Lee | Hold | Maintains | $36.00 |
| Nov 5, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $81.00 |
| Nov 5, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $100.00 |
| Oct 29, 2025 | Stifel | Alex Thompson | Buy | Maintains | $80.00 |
AnaptysBio Inc. (ANAB) Competitors
The following stocks are similar to AnaptysBio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AnaptysBio Inc. (ANAB) Financial Data
AnaptysBio Inc. has a market capitalization of $1.94B with a P/E ratio of -146.7x. The company generates $234.60M in trailing twelve-month revenue with a -5.6% profit margin.
Revenue growth is +151.1% quarter-over-quarter, while maintaining an operating margin of +61.8% and return on equity of -24.5%.
Valuation Metrics
Market Cap
$1.94B
Enterprise Value
$1.92B
P/E Ratio
-146.7x
PEG Ratio
0.4x
Price/Sales
8.3x
Growth & Margins
Revenue Growth (YoY)
+151.1%
Gross Margin
N/A
Operating Margin
+61.8%
Net Margin
-5.6%
EPS Growth
+151.1%
Financial Health
Cash/Price Ratio
+16.1%
Current Ratio
9.1x
Debt/Equity
781.1x
ROE
-24.5%
ROA
+7.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AnaptysBio Inc. (ANAB) Business Model
About AnaptysBio Inc.
What They Do
Develops immunology therapeutics for autoimmune diseases.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on the development of antibody-based therapeutics. It generates revenue through collaborations and partnerships, licensing its drug candidates to other pharmaceutical companies, which provides opportunities for milestone payments and royalties.
Additional Information
AnaptysBio has a diverse pipeline of candidates targeting various autoimmune and inflammatory conditions. Its headquarters in San Diego, California, positions it within a thriving biotech ecosystem. The company has established significant collaborations, including partnerships with GSK and Vanda Pharmaceuticals, enhancing its market reach and financial stability.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
104
CEO
Mr. Daniel R. Faga
Country
United States
IPO Year
2017
Website
www.anaptysbio.comAnaptysBio Inc. (ANAB) Latest News & Analysis
Latest News
Quick Summary
AnaptysBio, Inc. announced a $145 million private placement for its spin-off, First Tracks Biotherapeutics, with EcoR1 Capital as the selling stockholder.
Why It Matters
The $145 million private placement indicates strong investor interest and funding support for AnaptysBio's spin-off, potentially enhancing growth prospects and shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AnaptysBio, Inc. (Nasdaq: ANAB) has authorized a $100 million stock repurchase plan for its common stock. The company also provided a business update.
Why It Matters
AnaptysBio's $100M stock repurchase plan signals confidence in its financial health, potentially enhancing shareholder value and indicating a commitment to returning capital.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AnaptysBio, Inc. will spin off First Tracks Biotherapeutics, which will start trading on Nasdaq under the ticker "TRAX" on April 20, 2026.
Why It Matters
The spin-off of First Tracks Biotherapeutics creates a new investment opportunity, potentially unlocking value and allowing investors to focus on specialized growth in biotherapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AnaptysBio, Inc. (ANAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
1 month ago
Quick Summary
AnaptysBio, Inc. (ANAB) presented at the Barclays 28th Annual Global Healthcare Conference, discussing its developments and strategies.
Why It Matters
AnaptysBio's presentation at a key healthcare conference could signal strategic developments, partnerships, or financial outlook, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
AnaptysBio plans to spin off its biopharma operations into a public entity, First Tracks Biotherapeutics, in Q2 2026. Q4 2025 Jemperli sales reached $343 million, with expected royalties surpassing $390 million.
Why It Matters
The spin-off could unlock value for shareholders by separating assets, while strong Jemperli sales and royalties indicate robust revenue potential for AnaptysBio.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AnaptysBio, Inc. (ANAB) reported Q3 earnings of $1.58 per share, surpassing the Zacks Consensus Estimate of $0.89, compared to a loss of $0.72 per share in the same quarter last year.
Why It Matters
AnaptysBio's strong earnings beat indicates improved financial health and growth potential, likely boosting investor confidence and driving stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ANAB Stock
What is AnaptysBio Inc.'s (ANAB) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, AnaptysBio Inc. (ANAB) has a median price target of $75.00. The highest price target is $140.00 and the lowest is $50.00.
Is ANAB stock a good investment in 2026?
According to current analyst ratings, ANAB has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $67.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANAB stock?
Wall Street analysts predict ANAB stock could reach $75.00 in the next 12 months. This represents a 11.1% increase from the current price of $67.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AnaptysBio Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on the development of antibody-based therapeutics. It generates revenue through collaborations and partnerships, licensing its drug candidates to other pharmaceutical companies, which provides opportunities for milestone payments and royalties.
What is the highest forecasted price for ANAB AnaptysBio Inc.?
The highest price target for ANAB is $140.00 from at , which represents a 107.4% increase from the current price of $67.51.
What is the lowest forecasted price for ANAB AnaptysBio Inc.?
The lowest price target for ANAB is $50.00 from John Lee at Truist Securities, which represents a -25.9% decrease from the current price of $67.51.
What is the overall ANAB consensus from analysts for AnaptysBio Inc.?
The overall analyst consensus for ANAB is bullish. Out of 27 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $75.00.
How accurate are ANAB stock price projections?
Stock price projections, including those for AnaptysBio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 10:16 PM UTC